Repertoire uses its proprietary DECODE platform, combining experimental and computational tools, to map the full immune synapse and identify disease‑relevant epitopes and T‑cell receptors across all human HLA class I and II molecules. This enables the design of off‑the‑shelf, programmable immune medicines such as TCR‑bispecifics and mRNA vaccines for cancer and autoimmune diseases, offering high specificity and scalability for pharmaceutical partners.
Funding
$189M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current immunotherapies for cancer and autoimmune diseases are limited by low specificity, reliance on patient-specific manufacturing, and inadequate coverage of diverse HLA types, resulting in suboptimal efficacy and safety for many patients.
Solution
Repertoire leverages its proprietary DECODE platform—a suite of integrated experimental and computational technologies—to decode the full immune synapse, identifying disease-relevant epitopes and T‑cell receptors across all human HLA class I and II molecules. By mapping these immune codes, the company designs off‑the‑shelf, programmable immune medicines that precisely target tumors or restore immune tolerance. Their pipeline includes TCR‑bispecific therapeutics and mRNA cancer vaccines for solid and hematologic malignancies, as well as mRNA tolerizing vaccines for autoimmune disorders. Machine‑learning (NEPTUNE) integrates massive epitope‑TCR data to inform candidate selection, while proprietary MEDi, Multimer, and MCR technologies enable high‑throughput discovery of epitope presentation and TCR specificity. This approach aims to deliver highly specific, scalable therapies that are effective across diverse patient populations.
Target Audience
Primary customers are pharmaceutical and biotech companies developing immunotherapies for oncology and autoimmune indications, as well as clinical research programs seeking high‑resolution immune‑synapse data.
Features
- MEDi™ assesses disease‑associated antigen presentation across the full spectrum of human HLA class I and II molecules.
- Proprietary Multimer technology screens tens of millions of T cells to pinpoint epitope‑specific TCRs directly from patient samples.
- MCR™ platform de‑orphanizes up to 10 million peptide‑MHC combinations, determining TCR specificity for both CD4⁺ and CD8⁺ cells.
- NEPTUNE machine‑learning engine integrates epitope, TCR, and phenotype data to generate actionable insights for therapeutic design.
- Off‑the‑shelf TCR‑bispecific molecules combine high‑affinity tumor‑specific TCRs with anti‑CD3 to redirect endogenous T cells for tumor killing.
- mRNA cancer vaccines encode selected class I and II epitopes in lipid nanoparticles to elicit robust CD8⁺ and CD4⁺ responses.
- mRNA tolerizing vaccines encode tissue‑specific class II epitopes and an immune modulator to expand regulatory T cells and induce antigen‑specific anergy.
- Platform enables discovery of shared, HLA‑agnostic targets, supporting equitable therapy across diverse genetic backgrounds.